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MYELOID NEOPLASIA
EZH2 mutational status predicts poor survival in myelofibrosis
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We genotyped 370 subjects with primary
myelofibrosis (PMF) and 148 with
postpolycythemia vera/postessential
thrombocythemia (PPV/PET) MF for muta-
tions of EZH2. Mutational status at diagno-
sis was correlated with hematologic pa-
rameters, clinical manifestations, and
outcome. A total of 25 different EZH2
mutations were detected in 5.9% of PMF,
1.2% of PPV-MF, and 9.4% of PET-MF
patients; most were exonic heterozygous
missense changes. EZH2 mutation coex-
isted with JAK2V617F or ASXL1 mutation
in 12 of 29 (41.4%) and 6 of 27 (22.2%)
evaluated patients; TET2 and CBL muta-
tions were found in 2 and 1 patients,
respectively. EZH2-mutated PMF patients
had significantly higher leukocyte counts,
blast-cell counts, and larger spleens at
diagnosis, and most of them (52.6%) were
in the high-risk International Prognostic
Score System (IPSS) category. After a
median follow-up of 39 months, 128 pa-
tients (25.9%) died, 81 (63.3%) because of
leukemia. Leukemia-free survival (LFS)
and overall survival (OS) were signifi-
cantly reduced in EZH2-mutated PMF pa-
tients (P  .028 and P < .001, respec-
tively); no such impact was seen for PPV/
PET-MF patients, possibly due to the low
number of mutated cases. In multivariate
analysis, survival of PMF patients was
predicted by IPSS high-risk category,
a < 25% JAK2V617F allele burden, and
EZH2 mutation status. We conclude that
EZH2 mutations are independently asso-
ciated with shorter survival in patients
with PMF. (Blood. 2011;118(19):5227-5234)
Introduction
The identification of the JAK2V617F mutation1-4 represented a
seminal discovery in the field of Philadelphia-chromosome–
negative chronic myeloproliferative neoplasms (MPNs),5 provid-
ing clues to the pathogenesis,6 prompting a revision of the
diagnostic criteria,7 and culminating in the development of clinical
trials with JAK2 (and JAK1) inhibitors.8,9 The JAK2V617F muta-
tion occurs in almost all patients with polycythemia vera (PV) and
in 50%-70% of those with essential thrombocythemia (ET) and
primary myelofibrosis (PMF). Soon after the identification of the
JAK2V617F mutation, mutations in JAK2 exon 12 were described
in rare patients with JAK2V617F-negative PV and mutations in
MPL were reported in 5%-10% of ET or PMF subjects. The
complexity of the molecular pathogenesis of MPNs is reinforced
by discovery of additional mutations in TET2,10 ASXL1,11 CBL,12
IDH1/IDH2,13 and IKZF1.14 These mutations are detected in a
minority of patients at different phases of the disorder, including
leukemic transformation, and are variably associated each other
and with JAK2 or MPL mutations.
We recently identified novel loss-of-function mutations in
EZH2 in 1 of 30 (3%) PV and in 4 of 30 PMF patients (13%), as
well as in 11%-25% of patients with myelodysplastic syndromes
(MDS) and in 10% of patients with MDS/MPN.15 Mutations were
spread throughout the gene and included missense, nonsense, and
premature stop codons; both monoallelic and biallelic mutations
were described. Among patients with MDS/MPN, survival was
significantly worse in those with EZH2 mutation. Furthermore,
subjects with homozygous mutations had a trend toward inferior
survival compared with heterozygous patients.15 Several different
EZH2 mutations were also reported in an independent series of
102 patients with MDS,16 whereas a functionally distinct heterozy-
gous missense point mutation at codon Y641 of EZH2 has been
described in patients with follicular lymphoma (7%) and diffuse,
germinal center-origin, large B-cell lymphomas (22%).17,18
The aim of current study was to determine the frequency and
characteristics of EZH2 mutations in a large series of patients with
PMF and PPV/PET MF and to analyze the prognostic relevance of
a mutated EZH2 status.
Methods
Patients and samples
Patients diagnosed with PMF or PPV/PET-MF according to World Health
Organization (WHO)7 and International Working Group for Myelofibrosis
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Research and Treatment (IWG-MRT) criteria,19 respectively, were recruited
for this study from the database at 6 hematology units: Florence, Italy;
Pavia, Italy; Southampton, United Kingdom; Barcelona, Spain; Athens,
Greece; and Mannheim, Germany. For PET-MF patients, only those who
had a previous confirmed diagnosis of “true” ET as opposed to “prefibrotic”
MF were considered for this study. Patients provided informed consent for
the use of archival material for mutational analysis, and the study was
performed under a Florence University Institutional Review Board–
approved protocol in referring institutions. The study was conducted in
accordance with the Declaration of Helsinki.
Genotyping for EZH2 mutations
DNA was purified from peripheral blood (PB) whole leukocytes (n 71) or
gradient-purified granulocytes (n 447) that had been collected at diagno-
sis of PMF or PPV/PET-MF, or no later than 1 year afterward provided the
patient had remained free of cytotoxic treatment. DNA was purified using
conventional methods and subjected to whole-genome amplification with
the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare). EZH2
mutation analysis was performed using high-resolution melting (HRM) in a
Rotor-Gene 6000 instrument (Corbett Life Science), using primer sets as
described previously.15 Products showing abnormal melt pattern were
subjected to bidirectional direct sequencing. Sequence analysis was per-
formed using Mutation Surveyor (SoftGenetics). All mutations were further
validated by repeating PCR and direct sequencing on genomic (ie, not
subjected to whole-genome amplification) DNA from the archival sample.
Details of the techniques used are provided in supplemental Methods
(available on the Blood Web site; see the Supplemental Materials link at the
top of the online article).
Genotyping for JAK2, MPL, IDH1/IDH2, CBL, TET2, and ASXL1
mutations
Patients were also genotyped for additional mutations, including JAK2,
MPL, IDH1, IDH2, and ASXL1. The presence of the JAK2V617F mutation
and the mutated allele burden were determined by quantitative real-time
PCR (QRT-PCR)20 or pyrosequencing assays.21 MPLW515L/K mutations
were determined using QRT-PCR, as described previously.22 Mutational
analysis for IDH exon 4, ASXL1 exon 12, (primers are listed in supplemen-
tal Table 1) and CBL exons 8 and 912 was performed by direct sequencing of
the PCR products amplified from genomic DNA. The complete coding
sequence of TET2 was analyzed by HRM.15
Statistical analysis
Our primary aim was to determine the correlation between EZH2 muta-
tional status and major outcome events, which included overall survival
(OS) and transformation to acute leukemia. We also investigated whether
EZH2 status was correlated with specific laboratory parameters or clinical
features, including RBC indexes, leukocyte or platelet count, percentage of
PB blasts, splenomegaly, constitutional symptoms, and the ranking of
patients according to the International Prognostic Score System (IPSS)
developed by the IWG-MRT.23 Constitutional symptoms included loss of
10% or more of body weight in the last 6-months, drenching night sweats,
or unexplained fever. Splenomegaly was measured in centimeters from the
left costal margin (LCM); we considered 2 groups of patients who presented
a spleen enlargement smaller than or greater than 10 cm from the LCM,
respectively.
The 2 or Fisher exact test (2  2 table) or the 2 test for trend (larger
contingency table) were used as appropriate to compare the variables
among the different patient groups that had been categorized according to
mutational status. The analysis of continuous variables among the groups
was performed using the Mann-Whitney U test (2 groups) or the Kruskal-
Wallis test with the use of the Dunn method for multiple comparison.
Kaplan-Meier analysis and the log-rank test were used to estimate OS. Cox
regression models were used to perform multivariate analysis. P  .05 was
considered to indicate statistical significance; all tests were 2-tailed. Data
were processed using SPSS Version 17.0 software (StatSoft).
Results
Patient characteristics
Hematologic and clinical features of the 518 patients included in
the study are listed in supplemental Table 2; they comprised
370 subjects with PMF, 84 with PPV-MF, and 64 with PET-MF. A
total of 321 subjects were JAK2V617F mutated (62%): 213 with
PMF (58%), 78 with PPV-MF (93%), and 30 with PET-MF (47%).
The median V617F allele burden was 42% (range 3%-100%) in
PMF, 69% (range 11%-100%) in PPV-MF, and 48% (range
2%-100%) in PET-MF. Considering only patients with PMF, 31
(14.5%) had a V617F allele burden 25%. The MPLW515L/K
mutation was found in 18 patients (3.8%): 13 with PMF (3.7%) and
5 (10.6%) with PET-MF. Results of cytogenetic analysis at
diagnosis were available in 188 patients; of these, 21 with PMF
(15.3% of evaluated), 7 with PPV-MF (21.2%), and 6 with PET-MF
(33.3%) had unfavorable cytogenetic abnormalities (ie, complex
karyotype or single or 2 abnormalities including 8, 7/7q,
i(17q),5/5q, 12p, inv(3), or 11q23 rearrangement).24
The stratification of PMF patients according to the IPSS
reflected that reported in large patients series, with 30.7%, 25.5%,
22.4%, and 21.4% in the low-risk, intermediate 1–risk, intermedi-
ate 2–risk, and high-risk categories, respectively, indicating that
our patient population was well representative of all of the different
IPSS risk categories.
Results of EZH2 genotyping
We screened all of the 20 coding exons of EZH2 by HRM followed
by direct-sequencing confirmation. A total of 29 patients (5.6% of
total) were EZH2 mutated; of these, 22 had PMF (5.9% of all
PMF), 1 had PPV-MF (1.2%), and 6 had PET-MF (9.4%; supple-
mental Tables 2 and 3). Because only 1 of 84 PPV-MF patients was
EZH2 mutated, we carefully reviewed his records and confirmed
the original diagnosis of PV using the 2008 WHO criteria7 and the
diagnosis of progression to PPV-MF according to the IWG-MRT
criteria.19 This was a 62-year-old man who had a 14-year-long
history of heavily phlebotomized PV treated with hydroxyurea at
the time he was diagnosed as PPV-MF.
We identified a total of 25 different mutations, of which 20 were
exonic and 5 intronic. Seven mutations (in 9 patients) were located
in the suppressor of variegation3-9, enhancer of zeste and trithorax
(SET) domain and 4 (in 5 patients) in the CXC domain; other
mutations were located in exons 3, 5, 8, and 9 (Figure 1). Most
exonic mutations were heterozygous missense changes caused by
single-nucleotide substitution; in 5 patients (17%; patient numbers
2, 15, 17, 26, and 28 in supplemental Table 3), a homozygous
mutation was detected, including one intronic change (patient
number 26 in supplemental Table 3), and 1 patient presented with
2 different mutations (patient number 19 in supplemental Table 3).
Mutations were confirmed as somatic for 5 of 5 patients with
available germline DNA extracted from buccal epithelial cells:
74938G GA/G A (patient numbers 1 and 2), 54557T TA
(patient number 7), 73990G  C (patient number 10), and
70231C CT (patient numbers 11 and 12) abnormalities. Other
patients were denoted as having mutations based on the exclusion
of known single nucleotide polymorphisms in published databases
(Ensembl and National Center for Biotechnology Information).
Five intronic mutations were also identified (supplemental Figure
1); of these, 3 (patient numbers 25, 26, and 28) affected the
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absolutely conserved AG/GT exon flanking splice sites and are
therefore very likely to be causative. The changes in patients 27 and
29 are of uncertain significance, but were considered as causative
for the analysis below. Twelve EZH2-mutated subjects (41.4%)
harbored the JAK2V617F mutation; of these, 9 had PMF, 1 PPV-
MF, and 2 PET/MF. No EZH2-mutated patient had mutations in
IDH1/IDH2, whereas 6 of 27 evaluated subjects (22.2%) concur-
rently harbored an ASXL1 exon 12 mutation. The simultaneous
occurrence of the EZH2, JAK2V617F, and ASXL1 mutations was
not documented. Two patients had mutations in TET2, one of
whom was also ASXL1 mutated (patient number 6 in supplemental
Table 3). One additional patient (patient number 26) was EZH2,
CBL, and ASXL1 mutated. Finally, no concurrent EZH2 and
MPLW515L/K mutation was detected.
We also analyzed a prospective cohort of 118 PMF patients
who had EZH2 wild-type genotype at diagnosis and for whom
we had stored at least 1 additional blood sample collected after a
minimum of 1 year from diagnosis (median 38; range 12-84
months). Acquisition of the EZH2 mutation was demonstrated in
1 patient (patient number 13 in supplemental Table 3) at
32 months after diagnosis; she has been followed for an
additional 24 months without obvious changes in her illness.
Finally, in 1 EZH2/ASXL1–mutated PMF patient who evolved to
leukemia after 17.6 months from diagnosis (patient number 1 in
supplemental Table 3), the blast cells showed maintenance of
both mutations. In this patient, granulocytes collected at diagno-
sis and blast cells at leukemic transformation tested negative for
JAK2V617F, MPLW515L/K, TET2, IDH1/IDH2, and CBL muta-
tions. Conversely, none of 7 EZH2 wild-type PMF patients at
diagnosis who later evolved to leukemia acquired an EZH2
mutation. Of these, 5 were JAK2V617F mutated at chronic
phase and maintained this mutation in leukemic blasts.
Table 1. Hematologic and clinical characteristics of patients stratified according to EZH2 mutational status
PMF
P
PPV/PET-MF
P
EZH2 EZH2
Wild-type Mutated Wild-type Mutated
N 348 22 141 7
Median follow-up, mo, (range) (n  500)* 39.567 (1-340) 28.183 (8-183) .365 29.7 (1-234) 16.8 (1-70) .256
Median age, y (range) 60.0 (14-90) 66.0 (38-90) .135 62.0 (32-84) 62.0 (52-78) .731
Male sex, no. (%) (n  303)* 221 (60.6) 15 (68.2) .481 73 (51.8) 4 (57.1) .781
Leukocytes,  106/L, mean  SD (n  500)* 12.3  13.3 18.7  11.5 .001 14.3  14.1 13.8  7.0 .360
Hb, g/L, mean  SD (n  497)* 114  27 112  19 .700 114  26 100  18 .153
Platelets,  106/L, mean  SD, (n  501)* 341.0  345.6 405.0  258.7 .831 404.1  317.6 232.1  198.0 .097
Peripheral blast cells, %, mean  SD (n  329)* 0.7  2.1 1.6  2.1 .002 0.5  2.0 0.4  0.9 .959
Constitutional symptoms, no. (%) (n  333)* 67 (28.2) 8 (42.1) .198 34 (47.9) 2 (40.0) .733
Splenomegaly, no. (%) (n  494)*† .016 .059
0 91 (27.6) 1 (4.5) 17 (12.6) 3 (42.9)
1 141 (42.7) 9 (40.9) 58 (43.0) 1 (14.3)
2 98 (29.7) 12 (54.5) 60 (44.4) 3 (42.9)
Abnormal karyotype, no. (%) (n  195)* 26 (20.2) 4 (36.4) .209 17 (32.7) 2 (66.7) .229
Unfavorable karyotype, no. (%) (n  188)* 18 (14.3) 3 (27.3) .252 11 (22.9) 2 (66.7) .092
JAK2V617F, no. (%) (n  518)* 204 (58.8) 9 (40.9) .100 105 (74.5) 3 (42.9) .066
JAK2V617F allele burden, %, mean  SD 45.7  22.9 42.2  22.1 .603 64.1  23.4 61.1  52.6 .747
MPL W515L/K, no. (%) (n  466)* 13 (3.9) 0 (0.0) .344 5 (4.7) 0 (0.0) .586
IWG-MRT score, no. (%) (n  192)* .002 -
Low 55 (31.8) 4 (21.1)
Int-1 44 (25.4) 5 (26.3)
Int-2 43 (24.9) 0 (0.0)
High 31 (17.9) 10 (52.6)
Progression to acute leukemia, no. (%) (n  443)* 57 (17.6) 7 (31.8) .098 16 (17.2) 1 (20.0) .872
Death, no. (%) (n  494)* 86 (26.0) 13 (61.9)  .001 28 (20.6) 1 (16.7) .816
P values in bold indicate statistical significance.
*Number of patients for whom information was available.
†Splenomegaly: 0  not palpable; 1  palpable at  10 cm from left costal margin; and 2  palpable at  10 cm from left costal margin.
Figure 1. EZH2 schematic structure and localization
of mutations. (A) Representation of EZH2 exons. Blue
and purple bars correspond to exons encoding the
SANT_DNA–binding domain and the SET domain, re-
spectively. (B) Domain structure of EZH2 and positions of
mutations carried by subjects. Missense mutations high-
lighted in the violet boxes (R288Q, N322S, R690H, and
Y733X) have been described previously.15,42
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Association of EZH2-mutated genotype with hematologic and
clinical characteristics
To establish the correlation, if any, of the EZH2 mutation with
clinical characteristics, we compared EZH2-mutated PMF pa-
tients with their wild-type counterparts (Table 1). PMF patients
harboring an EZH2 mutation (including the 5 intronic variants)
displayed at diagnosis a higher leukocyte count (median 17.8;
range 3.5-47.9 vs 8.5  109/L; range 1.4-106, P  .001), more
frequently had a blast count  1% (52.6% vs 20.7%, P  .002),
and presented with a larger spleen (the proportion of those with
palpable spleen at  10 cm from the LCM was 54.5% vs 29.7%,
P  .016). Variables associated with leukocytosis in multivari-
ate analysis were: age  65 years (P  .030), presence of
constitutional symptoms (P  .018), and EZH2 mutation
(P  .023). Factors associated with  1% blast cells in univari-
ate analysis were ASXL1 mutation (P  .001), hemoglo-
bin  100 g/L (P  .001), leukocytosis ( 25  109/L)
(P  .001), and EZH2 mutation (P  .003); however, in multi-
variate analysis, EZH2 lost its significant association in favor of
the others. Finally, variables associated with splenomegaly  10
cm in univariate analysis were: the presence of constitutional
symptoms (P  .027), a  25% V617F allele burden (P  .014),
and EZH2 mutation (P  .019); however, all of these variables
lost their significant association in multivariate analysis.
Finally, there was no difference in age, sex, hemoglobin level,
platelet count, or occurrence of constitutional symptoms be-
tween EZH2 mutated and wild-type patients. The proportion of
the JAK2V617F mutation in the 2 groups was also similar
(40.9 vs 58.8%).
The analysis of the PPV/PET-MF patients did not reveal any
significant differences in terms of hematologic and clinical param-
eters that could be meaningfully associated with their EZH2
mutational status (Table 1). Similar results were obtained when
PET-MF patients (n 6) were considered separately from the
single PPV-MF–mutated patient (data not shown).
To assess whether EZH2 status was correlated with IPSS
prognostic score, we evaluated the distribution of PMF patients
in the different IPSS risk categories.23 We observed that most
EZH2-mutated patients (52.6%) clustered in the high-risk
category compared with the low-risk group (21.1%; P  .002).
The low number of EZH2-mutated patients who had cytogenetic
analysis available (n  11) did not allow us to ascertain the
correlation of EZH2 mutational status with the Dynamic IPSS
Plus (DIPPS Plus) score.24 However, the proportion of patients
with unfavorable karyotype was double among EZH2-mutated
versus wild-type subjects (27.3% vs 14.3% for PMF and 66.7%
vs 22.9% in PPV/PET-MF patients, respectively), although the
difference was not statistically significant possibly because of
the low number of patients.
We also stratified PMF patients according to 4 different
categories defined by their EZH2 and JAK2V617F mutational
status (Table 2). Among EZH2 wild-type subjects, the presence of
the JAK2V617F mutation was associated with significantly older
age, higher leukocyte and hemoglobin levels, and a lower fre-
quency of the MPLW515 mutation; conversely, there was no
difference with regard to sex, platelet count, PB blast cell count,
constitutional symptoms, splenomegaly, IPSS score, or proportion
of patients progressing to leukemia. In EZH2-mutated patients, the
concurrent presence of the JAK2V617F mutation did not affect the
hematologic or clinical phenotype at all (Table 2).
Association of EZH2-mutated genotype with disease outcome
Information about progression to acute leukemia and death were
available in 443 and 494 patients, respectively. After a median
Table 2. Hematologic and clinical characteristics of EZH2-mutated subjects with PMF stratified according to JAK2V617F mutational status
EZH2 wild-type
P
EZH2 mutated
P
JAK2 JAK2
Wild-type V617F Wild-type V617F
N 143 204 13 9
Follow-up, mo (range) n  354)* 49.4 (1-340) 37.9 (1-282) .020 25.7 (8-182) 30.7 (11-84) .616
Median age, y, (range) 55.0 (14-88) 63.0 (18-90) .001 57.0 (41-81) 70 (38-90) .324
Male sex, no. (%) (n  369)* 90 (62.9) 120 (58.8) .440 8 (61.5) 7 (77.8) .421
Leukocytes,  106/L, mean  SD (n  354)* 11.3  13.0 13.1  13.5 .005 16.2  11.5 22.4  11.1 .117
Hemoglobin, g/L, mean  SD (n  352)* 109  24 118  28 .002 107  22 118  14 .171
Platelet,  106/L, mean  SD (n  355)* 447.0  403.2 408.7  308.0 .840 392.8  255.0 422.5  278.6 .764
Peripheral blast cells, %, mean  SD (n  240)* 1.0  2.6 0.5  1.7 .090 1.4  2.4 1.8  1.8 .299
Constitutional symptoms, no. (%) (n  257)* 26 (28.3) 41 (28.1) .976 3 (27.3) 5 (62.5) .125
Splenomegaly, no. (%) (n  352)*† .747 .518
0 41 (29.7) 50 (26.0) 1 (7.7) 0 (0.0)
1 58 (42.0) 83 (43.2) 6 (46.2) 3 (33.3)
2 39 (28.3) 59 (30.7) 6 (46.2) 6 (66.7)
Unfavorable karyotype, no. (%) (n  137) 8 (12.1) 10 (16.7) .466 2 (28.6) 1 (25.0) .898
JAK2V617F allele burden, %, mean  SD 45.9  23.0 42.2  22.1
MPL W515L/K, no. (%) (n  354)* 12 (8.8) 1 (0.5)  .0001 0 (0.0) 0 (0.0)
IWG-MRT score, no. (%) (n  192)* .484 .247
Low 26 (36.6) 29 (28.4) 3 (27.3) 1 (12.5)
Int-1 14 (19.7) 30 (29.4) 4 (36.4) 1 (12.5)
Int-2 18 (25.4) 25 (24.5) 0 (0.0) 0 (0.0)
High 13 (18.3) 18 (17.6) 4 (36.4) 6 (75.0)
Progression to acute leukemia, no. (%) (n  345)* 26 (19.3) 31 (16.5) .520 6 (46.2) 1 (11.1) .083
Death, no. (%) (n  352)* 38 (27.7) 48 (24.7) .541 7 (53.8) 6 (75.0) .332
P values in bold indicate statistical significance.
*Number of patients for whom information was available.
†Splenomegaly: 0  not palpable; 1  palpable at  10 cm from left costal margin; and 2  palpable at  10 cm from left costal margin.
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follow-up of 39 months (range 1-340), 128 patients (25.9%) died;
of these, 99 had PMF (28.1% of all PMF), 18 had PPV-MF
(23.1%), and 11 had PET-MF (17.2%; supplemental Table 2). The
median survival was 128 months in PMF patients (95% confidence
interval [95% CI], 92-163) and 103.3 months (95% CI, 79-128) in
PPV/PET-MF (supplemental Figure 2A-B). Considering PMF
patients only, survival varied according to the 4 IPSS risk
categories (supplemental Figure 2C); the median survival was 264
months (95% CI, 50-478) in the low-risk category, was not reached
in the intermediate 1–risk category, 80 months (95% CI, 71-90) in
the intermediate 2–risk category, and 32 months (95% CI, 18-46) in
the high-risk category patients (P  .001). As reported previ-
ously,20,25 survival was also significantly reduced in JAK2V617F-
mutated PMF patients, who presented an allelic burden 25%
compared with higher allelic burden quartiles (supplemental Figure
2D). JAK2V617F allele burden had no impact on survival in
PPV/PET-MF patients (not shown), confirming previous findings.26
Among patients who died, 14 (13 with PMF and 1 with
PET-MF) and 114 were EZH2 mutated or wild-type, respec-
tively, corresponding to 51.9% and 24.4% of their respective
categories (P  .001). The median OS was significantly short-
ened in EZH2-mutated PMF patients (31.6 months; 95% CI,
23-43) compared with wild-type (137 months; 95% CI, 53-222;
P  .001; Figure 2A). Variables associated with reduced sur-
vival among PMF patients in univariate analysis were sex, IPSS
score, low platelet count, low ( 25%) JAK2V617F allele
burden, and EZH2-mutated status (Table 3). On multivariate
analysis, OS was predicted by IPSS score (P  .0001), a  25%
JAK2V617F allele burden (P  .046), and EZH2-mutated status
(P  .016; Table 3). The significant association between EZH2
mutation and OS was maintained even if the 3 intronic
mutations in PMF subjects (supplemental Table 3) were not
considered as causative; in this case, OS was 32.3 months (95%
CI, 21.7-43.0) in EZH2-mutated patients (P  .0001 vs EZH2
wild-type). Finally, the fact that only one event was recorded in
the PPV/PET-MF group prevented statistical analysis of sur-
vival between EZH2-mutated and wild-type patients.
Acute leukemia occurred in 81 patients (18.3%), corresponding
to 19%, 14%, and 21% of PMF, PPV-MF, and PET-MF patients,
respectively. Among these, 73 were EZH2 wild-type (17.5%) and
8 EZH2 mutated (26.9%). The leukemia-free survival (LFS),
measured from diagnosis to the time of leukemia transformation,
was significantly shorter in EZH2-mutated PMF patients (n 7;
153.1 months, 95% CI, 42-264) compared with EZH2 wild-type
patients (n 57; 201.07 months, 95% CI, 103-299; P  .028)
(Figure 2B). Again, the significant association between EZH2
mutation and LFS was maintained without the 3 intronic mutations;
in this case, LFS was 84.2 months (95% CI, 12.9-155.5) in
EZH2-mutated patients (P  .014 vs EZH2 wild-type). The low
number of cases harboring the EZH2 mutation prevented any
multivariate analysis of variables associated with reduced LFS.
Due to low number of events, we were unable to determine the
statistical significance of EZH2 mutational status for LFS in the
PPV/PET-MF group.
Discussion
PMF is associated with poorer survival compared with other classic
BCR-ABL–negative chronic MPNs.27 The identification of vari-
ables associated with prognosis is of considerable importance for
driving therapeutic decisions, particularly concerning the choice
between drug therapy and hematopoietic stem cell transplanta-
tion,28 which remains the only potentially curative therapeutic
approach even in the era of JAK2 inhibitors. The IPSS, which
includes older age, the presence of constitutional symptoms,
anemia, leukocytosis, and blood blasts 1% as risk variables,
reliably discriminated 4 categories of patients with significantly
different median survival times of 135, 95, 48, and 27 months.23
Further refinement of the IPSS are the DIPSS 29 and the DIPSS Plus
score, which includes cytogenetic abnormalities, transfusion depen-
dency, and thrombocytopenia as additional variables.24 Several
studies have focused on the newly discovered somatic mutations in
MPNs to ascertain their relationships with disease phenotype and,
eventually, their prognostic value. Although with conflicting re-
sults, the presence of JAK2V617F in patients with PMF has been
associated with older age, higher leukocyte and RBC indexes, and
splenomegaly.25,30-32 However, most studies concluded that the OS
of JAK2V617F-mutated patients was no different from their
wild-type counterparts.20,25,31 Conversely, quantitative analysis of
the V617F allele burden revealed a prognostically negative impact
Table 3. Univariate and multivariate analysis for OS in PMF patients
Hazard ratio (95% CI) P
Univariate
Male sex 0.547 (0.358-0.835) .005
IPSS score 4.807 (2.807-8.232)  .0001
Platelet count  100  109/L 0.999 (0.998-0.999)  .0001
EZH2 mutation 2.817 (1.565-5.072) .001
V617F burden  25% 2.256 (1.034-4.921) .040
Multivariate
IPSS score 6.087 (2.723-13.606)  .0001
EZH2 mutation 3.585 (1.274-10.091) .016
V617F burden  25% 1.082 (1.014-1.101) .046
Figure 2. OS (A) and LFS (B) measured from disease diagnosis to leukemia
transformation in EZH2-mutated and wild-type patients with PMF.
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of a low allele burden (ie, the lowest quartile) in 2 independent
series from the GIMEMA group20 and the Mayo Clinic.25 In
patients with PPV-MF or PET-MF, no meaningful differences in
survival were found depending on the mutated status and allelic
burden of the JAK2V617F mutation.26 Finally, there is conflicting
information about the prognostic relevance of a nullizygous status
for the JAK2 predisposition haplotype 46/1 (“GGCC”).33,34 Other
mutated genotypes, including MPLW515L/K,35,36 CBL,12 TET2,10
ASXL1,11 LNK,37,38 and IDH1/IDH2,39 have not been shown to be
prognostically informative, although most patient series analyzed
to date were too small to allow reliable statistical analyses.40 The
aim of the present study was to clarify the prognostic relevance, if
any, of newly discovered mutations in EZH2 in a large series of
patients with PMF.
EZH2, the PcG Enhancer of Zeste Homolog 2, is the catalytic
component of the polycomb repressive complex 2 (PRC2), which
serves to trimethylate histone H3 lysine 27 (H3K27me3). It
contains 3 main functional domains: the SANT1 and SANT2
domains, which are involved in DNA binding; a cysteine-rich
(CXC) domain; and the catalytically active SET domain. H3K27
methylation by EZH2 requires the presence of 2 additional
proteins: embryonic ectoderm development (EED) and suppressor
of zeste 12 (SUZ12). PRC2 complexes contain other proteins,
including PHD finger protein 1 (PHF1), which specifically pro-
motes H3K27 trimethylation rather than dimethylation; sirtuin
1 (SIRT1); and jumonji, AT rich interactive domain 2 (Jarid2).
Trimethylation at H3K27 results in transcriptional repression, as
opposed to H3K4 trimethylation, catalyzed by the trithorax ho-
molog myeloid/lymphoid leukemia (MLL), which is associated
with transcriptional activation.
The gene encoding EZH2 is located at 7q36.1, comprises
20 exons, and extends for  40 kb. Macro- and microdeletions
specifically involving this region have been found in about 10% of
MDS patients,41 and a few patients had loss-of-heterozygosity
because of acquired uniparental disomy.15,16 Mutations of EZH2
have been reported in patients with PMF, MDS, MDS/MPN,15,16,42
and lymphoma.17,18 Unlike the heterozygous, gain-of-function
missense mutation of Tyr641 in the SET domain that occurs in
lymphoma43 and the overexpression of EZH2 seen in epithelial
malignancies, mutations in MPN and MDS are scattered through-
out the gene and result in loss of function. These data indicate that
EZH2 may behave as a tumor suppressor or an oncogene depend-
ing on the cellular context, presumably by controlling chromatin
structure and gene accessibility.44
In this large cohort of 518 patients with MF, EZH2 mutations
were detected in approximately 6% of PMF patients, 9% of
PET-MF patients, and only in only 1 PPV-MF patient (1.2%). Such
a frequency is lower than originally reported in a smaller group of
30 subjects (13%),15 but is similar to a recent study that included
46 PMF cases (7%).45 EZH2-mutated patients concurrently har-
bored JAK2V617F, CBL, TET2, and ASXL1 mutations in 41.4%,
5.9%, 11.8%, and 22.2%% of cases, respectively. No EZH2-
mutated patients also harbored a MPL mutation; however, these
2 rare molecular abnormalities are not necessarily mutually exclu-
sive, because at least one such case has been described recently.45
IDH1/IDH2 mutations, reported preferentially in patients in leuke-
mic transformation,39 were not detected in association with EZH2
mutations. Finally, in a prospective cohort of 118 PMF patients followed
for a median of 39 months who tested negative for EZH2 mutation at
diagnosis, only one became EZH2 mutation positive. Whereas we
cannot exclude that this mutation was already present at very low level
at diagnosis and went undetected, these data suggest that EZH2
mutations are usually already present at the time of diagnosis. In
addition, we found that EZH2 mutations can be maintained in leukemic
blasts at the time of leukemia transformation, as described for
JAK2V617F.46 On the contrary, we found no evidence for EZH2
mutations being acquired at the time of leukemia transformation in any
of the 8 patients who were wild-type at diagnosis.
The analysis of hematologic-clinical correlates highlighted only
subtle differences associated with the EZH2 mutation in PMF
patients, such as more pronounced leukocytosis, larger spleens, and
higher circulating blast cells; therefore, we conclude that the EZH2
mutation does not contribute a specific phenotypic signature in
patients with primary and PPV/PET PMF. Conversely, we found
that EZH2 mutational status had a significant negative impact on
disease outcome among PMF patients. This is supported by the
following findings: (1) EZH2-mutated patients preferentially clus-
tered in the IPSS high-risk category; (2) both OS and LFS were
shortened in EZH2-mutated subjects compared with their wild-type
counterparts; and (3) in a multivariate analysis, EZH2 mutational
status maintained a negative prognostic significance together with
the IPPS score and a low JAK2V617F allele burden. We believe
that it is very unlikely that the adverse impact of the EZH2 mutation
could be attributable to mutations in another gene known to be
mutated in PMF, because there is no consistent evidence of an
association between changes in CBL, TET2, and LNK and a poor
prognosis in myeloid disorders,12,47,48 and because we found that
only 6 of 27 (22.2%) evaluable EZH2-mutated cases were also
mutated for ASXL1. Furthermore, it is noteworthy that a negative
prognostic impact of the EZH2 mutation on survival has also been
reported for patients with MDS/MPN, chronic myelomonocytic
leukemia, and MDS.15,16 Conversely, the low number of events
(death and leukemia) recorded in the PPV/PET-MF group pre-
vented statistical testing of a possible impact of EZH2 mutational
status on OS and LFS; data from a larger series of patients are
needed before any firm conclusion can be drawn.
Our series was representative of the usual distribution of
patients in the 4 IPSS-defined risk categories; however, the median
survival of the entire cohort, and in particular that of 13 patients
falling in the low- and intermediate 1–risk group, was longer than
reported in the original IPSS cohort.23 This is probably a conse-
quence of the relatively short follow-up time for our patients
compared with the IPSS study; indeed, disease-related deaths in the
low- and intermediate 1–risk categories occurred after 5 and
3 years, respectively, unlike the higher-risk groups, in which
disease-related deaths typically occurred much earlier. Therefore,
the prognostic impact of the EZH2 mutation could be even greater
than reported herein once a greater number of events are accrued
with longer follow-up times.
In summary, the results of this study indicate that an EZH2-
mutated genotype represents a novel variable independently associ-
ated with adverse outcome in patients with PMF. The pathoge-
netic mechanisms underlying this correlation remain to be
established, but nonetheless there is increasing evidence that
disruption of the epigenetic machinery by mutations in genes such
as EZH2, TET2, and ASXL1 makes an important contribution to the
pathogenesis of MPN, and might therefore represent novel therapeu-
tic targets.49
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